Početna stranicaNTLA • NASDAQ
add
Intellia Therapeutics Inc
Preth. zaklj. cijena
10,99 $
Dnevni raspon
10,11 $ - 10,77 $
Godišnji raspon
9,25 $ - 34,87 $
Tržišna kapitalizacija
1,05 mlr. USD
Prosječna količina
2,85 mil.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 9,11 mil. | −24,02 % |
Operativni troškovi | 30,50 mil. | 3,73 % |
Neto dohodak | −135,71 mil. | −11,04 % |
Neto profitabilnost | −1,49 tis. | −46,15 % |
Zarada po dionici | −1,34 | 2,90 % |
EBITDA | −142,16 mil. | −10,36 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 658,11 mil. | −23,01 % |
Ukupna imovina | 1,17 mlr. | −5,63 % |
Ukupne obveze | 210,74 mil. | 2,33 % |
Ukupni kapital | 962,62 mil. | — |
Dionice u optjecaju | 101,85 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 1,16 | — |
Povrat imovine | −30,61 % | — |
Povrat kapitala | −33,80 % | — |
Tok novca
Neto promjena novca
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −135,71 mil. | −11,04 % |
Gotovina od poslovanja | −84,84 mil. | 16,32 % |
Gotovina iz ulaganja | −7,71 mil. | −109,70 % |
Gotovina iz financiranja | 82,19 mil. | 330,28 % |
Neto promjena novca | −10,35 mil. | −272,58 % |
Slobodan tok novca | −35,80 mil. | 44,08 % |
Više
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Glavni izvršni direktor
Osnovano
2014
Web-lokacija
Zaposlenici
526
